-transparent.png){kind=logo}
-Angiotensin converting enzyme (ACE) inhibitors can limit mortality and the occurrence of cardiac failure after myocardial infarction because they interfere with the ventricular remodelling process. ACE inhibitors also have anti-arrhythmic and possibly anti-ischaemic potency and therefore a primary cardioprotective effect. It is not advised to treat all patients with a myocardial infarction with an ACE inhibitor, but patients with a large anterior wall infarct, with heart failure or who had a previous infarct should be treated. After three months, the remodelling process can be reevaluated. The ACE inhibitor can be discontinued if the left ventricular function has strongly improved. There is no preference for a particular ACE inhibitor.
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
October 1994,
Deutsche medizinische Wochenschrift (1946),
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
June 1993,
Clinical and experimental pharmacology & physiology,
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
January 1994,
Giornale italiano di cardiologia,
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
June 1995,
Journal of the American College of Cardiology,
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
January 2009,
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
October 1995,
The American journal of physiology,
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
March 1998,
Casopis lekaru ceskych,
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
January 2007,
Preventive cardiology,
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
August 1995,
Cardiology clinics,
D E de Waard, and
O Kamp, and
F C Visser, and
C A Visser
April 2001,
Journal of cardiovascular pharmacology,
